Robert Scheider, PhD
Dr. Robert Schneider is the Albert Sabin Professor of Molecular Pathogenesis at NYU School of Medicine, Associate Director of the NYU Cancer Institute, Breast Cancer Program Co-Director and Associate Dean for NYU Ventures and Partnerships. He has published more than 140 peer-reviewed papers. His research is directed to the development, progression, and metastasis of breast cancer and the interplay of the inflammatory response, and the development of new therapeutics for metastatic breast cancer.
Arthur Klausner is currently CEO of Goldilocks Therapeutics, Inc., a start-up company formed to advance nanoparticle technology developed at the Memorial Sloan Kettering Cancer Center for the treatment of acute kidney injury. He currently also serves as boardmember of Monopar Therapeutics, Cennerv Pharmaceutical, and Gem Pharmaceuticals. Prior to his operating roles, Arthur spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures.
Muna Abu-Shar, JD, PhD
Muna Abu-Shaar is an intellectual property attorney with over fifteen years of experience in patent counseling for biotechnology and pharmaceutical industry clients ranging from startups to Fortune 500 companies. Muna has a molecular biology technical background with experience in biologics (including antibodies and enzymes), pharmaceutical formulations, vaccines, diagnostics, recombinant technologies, and manufacturing processes. Muna received a J.D. from Fordham Law School, a Ph.D. in Cellular, Molecular & Biophysical Studies from Columbia University, and a B.A. in Natural Sciences from the University of Cambridge.
Megan Baier, JD,
Megan Baier is a partner at Wilson Sonsini Goodrich & Rosati, where she focuses on corporate and securities law, including general corporate representation, public offerings, venture capital financings, and mergers and acquisitions within the life sciences, healthcare, and technology sectors. Megan has assisted with matters ranging from formation and early-stage venture financing to listings of publicly traded securities on U.S. exchanges. She also has experience counseling publicly held companies on general corporate representation, mergers and acquisitions, SEC compliance, disclosure matters, and complex securities law issues. Prior to joining Wilson Sonsini, Megan practiced law at Ropes & Gray and Skadden Arps Slate Meagher & Flom in New York and Chicago.